Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer

被引：0

作者：

Alice Mogenet

Pascal Finetti

Emilie Denicolai

Laurent Greillier

Pascaline Boudou-Rouquette

François Goldwasser

Gwenael Lumet

Michele Ceccarelli

Daniel Birnbaum

Davide Bedognetti

Emilie Mamessier

Fabrice Barlesi

François Bertucci

Pascale Tomasini

机构：

[1] Aix Marseille Univ,Multidisciplinary Oncology and Therapeutic Innovations Department

[2] APHM,Centre de Recherche en Cancérologie de Marseille (CRCM), INSERM UMR1068, CNRS UMR725, Laboratoire d’Oncologie Prédictive

[3] INSERM,Department of Medical Oncology, Cochin Hospital, AP

[4] CNRS,HP, Paris

[5] CRCM,Sylvester Comprehensive Cancer Center, Department of Public Health Sciences

[6] Hôpital Nord,Division of Translational Medicine, Research Branch

[7] Aix Marseille Univ,Department of Internal Medicine and Medical Specialties

[8] France–University of Paris Descartes,Department of Medical Oncology, Institut Paoli

[9] ARIANE,Calmettes

[10] CARPEM,undefined

[11] University of Miami Miller School of Medicine,undefined

[12] Sidra Medicine,undefined

[13] University of Genoa,undefined

[14] Paris-Saclay University and Medical Oncology,undefined

[15] Gustave Roussy,undefined

[16] Aix Marseille Univ,undefined

来源：

Journal of Translational Medicine | / 21卷

关键词：

Lung cancer; ICR signature; Immune therapy; Biomarkers; Immune checkpoints inhibitors; Transcriptomics;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 322 条

[1] Sung H(2021)Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries CA Cancer J Clin 71 209-249
[2] Ferlay J(2022)Targeted therapies for lung cancer patients with oncogenic driver molecular alterations J Clin Oncol 40 611-625
[3] Siegel RL(2015)The journey from discoveries in fundamental immunology to cancer immunotherapy Cancer Cell 27 439-449
[4] Laversanne M(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-1639
[5] Soerjomataram I(2016)Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer N Engl J Med 375 1823-1833
[6] Jemal A(2018)Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer N Engl J Med 378 2078-2092
[7] Tan AC(2022)Predictive biomarkers for immunotherapy in lung cancer: perspective from the international association for the study of lung cancer pathology committee J Thorac Oncol 17 1335-1354
[8] Tan DSW(2017)PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data Immunotherapy 9 499-506
[9] Miller JFAP(2015)Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol 10 985-989
[10] Sadelain M(2018)The clinical utility of tumor mutational burden in non-small cell lung cancer Transl Lung Cancer Res 7 639-646